☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Evaluate
Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSC...
October 14, 2021
Asieris Receives NMPA's IND Approval to Evaluate APL-1202 + Tislelizumab as Neoadjuvant Therapy for MIBC Patients
October 14, 2021
Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSC...
October 14, 2021
Asieris Receives NMPA's IND Approval to Evaluate APL-1202 + Tislelizumab as Neoadjuvant Therapy for MIBC Patients
October 14, 2021
Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II S...
October 8, 2021
Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II S...
October 8, 2021
Load more...
Back to Home